Search: WFRF:(Danese Silvio) >
Clinical Practice o...
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
-
- Reinisch, Walter (author)
- Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
-
- Gecse, Krisztina (author)
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands
-
- Halfvarson, Jonas, 1970- (author)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology
-
show more...
-
- Irving, Peter M. (author)
- Department of Gastroenterology, Guy's and St. Thomas' NHS Foundation Trust, London, UK
-
- Jahnsen, Jørgen (author)
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
-
- Peyrin-Biroulet, Laurent (author)
- Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France
-
- Rogler, Gerhard (author)
- Department of Gastroenterology and Hepatology, University Hospital, University of Zurich, Zurich, Switzerland
-
- Schreiber, Stefan (author)
- Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany; Clinic of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany
-
- Danese, Silvio (author)
- IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy
-
show less...
-
(creator_code:org_t)
- 2020-07-07
- 2021
- English.
-
In: Inflammatory Bowel Diseases. - : Lippincott-Raven Publishers. - 1078-0998 .- 1536-4844. ; 27:1, s. 106-122
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://academic.oup...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goals beyond symptomatic relief and toward cessation of objective signs of inflammation, including endoscopic remission. Even though these agents are widely used for the treatment of moderate to severe CD, heterogeneity still exists in translating evidence-based guidelines on the use of anti-TNF agents into actual treatment algorithms in CD. This might be due to several reasons including disparities in health expenditure policies; lack of harmonization between countries; and variations in assessment of disease severity, use of disease monitoring tools, or application of treatment targets by physicians. With the advent of biosimilars, patent-free versions of reference biologics are now available to minimize health inequalities in drug availability. In this context, this article aims to provide practical clinical guidance for the use of infliximab and adalimumab biosimilars in patients with moderate to severe CD by outlining different clinical scenarios that patients may encounter during their treatment journey.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Keyword
- Biomarkers
- clinical trials
- endoscopy
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database